ABSTRACT
Studies on trabecular bone score (TBS) in psoriasis are lacking. We aim to assess the association between TBS and inflammation, metabolic syndrome features, and serum adipokines in 29 nondiabetic patients with psoriasis without arthritis, before and after 6-month adalimumab therapy. For that purpose, adjusted partial correlations and stepwise multivariable linear regression analysis were performed. No correlation was found between TBS and disease severity. TBS was negatively associated with weight, BMI, waist perimeter, fat percentage, and systolic and diastolic blood pressure before and after adalimumab. After 6 months of therapy, a negative correlation between TBS and insulin resistance (p = 0.02) and leptin (p = 0.01) and a positive correlation with adiponectin were found (p = 0.01). The best set of predictors for TBS values at baseline were female sex (p = 0.015), age (p = 0.05), and BMI (p = 0.001). The best set of predictors for TBS following 6 months of biologic therapy were age (p = 0.001), BMI (p < 0.0001), and serum adiponectin levels (p = 0.027). In conclusion, in nondiabetic patients with moderate-to-severe psoriasis, TBS correlates with metabolic syndrome features and inflammation. This association is still present after 6 months of adalimumab therapy. Moreover, serum adiponectin levels seem to be an independent variable related to TBS values, after adalimumab therapy.
ABSTRACT
OBJECTIVE: This study sought to assess whether the association between statin use and bone mineral density (BMD) and bone turnover markers is modulated by serum 25-hydroxyvitamin D (25OHD) levels in postmenopausal women. Design, Participants, and Settings: Approximately 1422 postmenopausal women were recruited from the Camargo Cohort after excluding those with any known medical disorder or drug that might affect bone metabolism. Participants were categorized into four groups: 25OHD levels of 20 ng/mL or less and not taking statins (group 1; n = 492); 25OHD levels greater than 20 ng/mL and on statins (group 2; n = 143); 25OHD levels of 20 ng/mL or less and using statins (group 3; n = 112); and 2OHD levels greater than 20 ng/mL and non-statin use (group 4; n = 675). Multivariate analyses were performed to compare BMD and bone turnover markers between groups. RESULTS: Women in group 2 had an adjusted femoral neck and total hip BMD higher than women in group 1 (P < .0001 and P = .003, respectively). A trend toward a significant difference was observed regarding lumbar BMD (P = .08). Serum aminoterminal propeptide of type 1 collagen and C-terminal telopeptide of type 1 collagen levels were lower in group 2 than in group 1, in crude and adjusted models, although only serum C-terminal telopeptide of type 1 collagen difference was significant (P = .009). CONCLUSIONS: Women on statins and serum 25OHD levels above 20 ng/mL have greater BMD and less bone resorption than those without either of the factors. Differences, however, are not significant in women with only one of them. Vitamin D and statins seem to interact positively in their effects on bone metabolism.
Subject(s)
Bone Density/drug effects , Bone Remodeling/drug effects , Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use , Osteoporosis, Postmenopausal/drug therapy , Postmenopause/drug effects , Vitamin D/analogs & derivatives , Aged , Biomarkers/blood , Bone Density/physiology , Bone Remodeling/physiology , Collagen Type I/blood , Female , Humans , Middle Aged , Multivariate Analysis , Osteoporosis, Postmenopausal/metabolism , Postmenopause/metabolism , Vitamin D/bloodABSTRACT
INTRODUCTION: In 2009 a deep change in ARV treatment took place in Spain with the introduction of new ARV drugs. The principal objective of the study was to determine the clinical situation of the patients in which DRV/r was introduced in the ARV therapy. METHODS: Observational, cross sectional and multicentre study in which 91 reference hospitals participated. Patient's enrollment was carried out between 2008 and 2009. Data were collected retrospectively considering standard clinical practice. RESULTS: 719 medical records were reviewed. Patients had a different clinical situation compared to nowadays with predominance of multiresistant virus which leaded to virologic failure. The principal reason for introducing DRV/r in the ARV regimen was the virologic failure (54.2%). CONCLUSIONS: Considering this situation, DRV/r became a therapeutic option which represented a change in the ARV paradigm in that period.
Subject(s)
Antiretroviral Therapy, Highly Active/methods , HIV Infections/drug therapy , HIV Protease Inhibitors/therapeutic use , Sulfonamides/therapeutic use , Adolescent , Adult , Age Factors , Antiretroviral Therapy, Highly Active/statistics & numerical data , Antiretroviral Therapy, Highly Active/trends , Cross-Sectional Studies , Darunavir , Drug Resistance, Viral , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Retrospective Studies , Sex Factors , Socioeconomic Factors , Spain , Treatment Outcome , Viral Load , Young AdultABSTRACT
Introducción. En el año 2009 se produjo un cambio muy sustancial en el tratamiento antirretroviral (ARV) de nuestro país con la introducción de nuevos fármacos antiretrovirales. El objetivo fue conocer la situación clínica de los pacientes en los que se introducía darunavir (DRV/r) en el tratamiento antirretroviral. Métodos. Estudio observacional, transversal y retrospectivo, en el que participaron 91 centros españoles de referencia. El periodo de reclutamiento del estudio se llevó a cabo entre 2008 y 2009. Se recogieron datos relacionados con la práctica clínica habitual. Resultados. Se revisaron 719 historias clínicas. La situación clínica prevalente entre los pacientes que necesitaban un ajuste al tratamiento antirretroviral era diferente a la actual con predominio de multirresistencias que llevaban a fracaso. El motivo principal por el que se había incluido DRV/r en la pauta fue el fracaso virológico (54,2%). Conclusiones. En esa situación, DRV/r constituyó una opción terapéutica que supuso un cambio en el paradigma del tratamiento antirretroviral de la época(AU)
Introduction. In 2009 a deep change in ARV treatment took place in Spain with the introduction of new ARV drugs. The principal objective of the study was to determine the clinical situation of the patients in which DRV/r was introduced in the ARV therapy. Methods. Observational, cross sectional and multicentre study in which 91 reference hospitals participated. Patients enrolment was carried out between 2008 and 2009. Data were collected retrospectively considering standard clinical practice. Results. 719 medical records were reviewed. Patients had a different clinical situation compared to nowadays with predominance of multiresistant virus which leaded to virologic failure. The principal reason for introducing DRV/r in the ARV regimen was the virologic failure (54.2%). Conclusions. Considering this situation, DRV/r became a therapeutic option which represented a change in the ARV paradigm in that period(AU)
Subject(s)
Humans , Male , Female , Adult , Middle Aged , Anti-Retroviral Agents/therapeutic use , Immunologic Deficiency Syndromes/drug therapy , Acquired Immunodeficiency Syndrome/drug therapy , Cross-Sectional Studies/methods , Cross-Sectional Studies , Retrospective Studies , Enzyme-Linked Immunosorbent Assay/methods , Enzyme-Linked Immunosorbent Assay , Blotting, WesternABSTRACT
No disponible
Subject(s)
Humans , Female , Adult , Epilepsy, Reflex/diagnosis , Hot Temperature/adverse effects , Paresthesia/etiology , Risk FactorsABSTRACT
No disponible
Subject(s)
Humans , Female , Adult , Bariatric Surgery/methods , Bariatric Surgery/psychology , Bariatric Medicine/methods , Polysomnography , Sleep Initiation and Maintenance Disorders/complications , Sleep Initiation and Maintenance Disorders/diagnosis , Sleep Apnea Syndromes/complications , Sleep Apnea Syndromes/diagnosis , Sleep Apnea, Obstructive/complications , Sleep Apnea, Obstructive/diagnosis , Electroencephalography , Obesity/complications , Bariatric Medicine/education , Bariatric Medicine/ethics , Polysomnography/trends , Obesity/psychology , Obesity , Sleep Wake Disorders/complications , Sleep Apnea, Obstructive/physiopathology , Sleep Apnea, Obstructive/therapySubject(s)
HIV Infections/drug therapy , HIV-1 , Nevirapine/therapeutic use , Reverse Transcriptase Inhibitors/therapeutic use , Zidovudine/administration & dosage , Adult , CD4 Lymphocyte Count , Chemical and Drug Induced Liver Injury/etiology , Cholesterol/blood , Cholesterol, HDL/blood , Dideoxynucleosides/administration & dosage , Dideoxynucleosides/adverse effects , Dideoxynucleosides/therapeutic use , Drug Therapy, Combination , Dyslipidemias/blood , Dyslipidemias/chemically induced , Female , HIV Reverse Transcriptase/antagonists & inhibitors , HIV-1/drug effects , Humans , Lamivudine/administration & dosage , Lamivudine/adverse effects , Lamivudine/therapeutic use , Male , Middle Aged , Nevirapine/administration & dosage , Nevirapine/adverse effects , Prospective Studies , Reverse Transcriptase Inhibitors/administration & dosage , Reverse Transcriptase Inhibitors/adverse effects , Viral Load , Zidovudine/adverse effects , Zidovudine/therapeutic use , gamma-Glutamyltransferase/bloodABSTRACT
No disponible
